Viatris (VTRS) Tmuɣli n wazal
Viatris
Asnulfu n AI: VTRS
AI tessawal ɣef timaqsiṭ n wazal i wass n tnekkit d-iteddun, taggara n yimal akked taggara n waggʷas. Asnifel yettwamḍen seg wazal aneggaru. Aya d tinineḍ n tḥisabt, ma tga ara timsisi n usihel.
Asref n 6 isggʷasn ineggura
Premium tessaɣ-d iswiyat n tɣara n AI i wass, amalas d waggʷas n yiwen i uḍris-a akk d yisɣunan niḍen.
Serreḥ Premium🔒 Tazmilt n usenfar
Amezruy n tmuɣliyin — akk tmuɣliyin n zik akked wazal n tnekkit — d akcum n Premium.
Serreḥ PremiumƔef tneɣlaft-a
On November 16, 2020, Viatris Inc. was formed through the successful merger of Mylan N.V. and Pfizer’s Upjohn business unit. Leveraging the heritage of these two complementary businesses, Viatris possesses scientific, manufacturing, and logistics infrastructure, as well as significant expertise in regulatory, medical, and commercial matters, enabling it to provide patients with quality medicines in more than 165 countries.
